CoChat
Sign Up
Cited by 173

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease

Fessler, Michael B.·2018·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2017.07.010PMC PMC5743771
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2017.07.010

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 128

  1. A-Gonzalez, 2009, Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR, Immunity, 31, 245, 10.1016/j.immuni.2009.06.018 · DOI
  2. A-Gonzalez, 2013, The nuclear receptor LXRalpha controls the functional specialization of splenic macrophages, Nature Immunology, 14, 831, 10.1038/ni.2622 · DOI
  3. Asquith, 2009, Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis, Arthritis and Rheumatism, 60, 2655, 10.1002/art.24717 · DOI
  4. Asquith, 2011, Simultaneous activation of the liver X receptors (LXRalpha and LXRbeta) drives murine collagen-induced arthritis disease pathology, Annals of the Rheumatic Diseases, 70, 2225, 10.1136/ard.2011.152652 · DOI
  5. Azzam, 2012, Crosstalk between reverse cholesterol transport and innate immunity, Trends in Endocrinology and Metabolism, 23, 169, 10.1016/j.tem.2012.02.001 · DOI · Paper page
  6. Babiker, 1999, Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: Evidence that most of this steroid in the circulation is of pulmonary origin, Journal of Lipid Research, 40, 1417, 10.1016/S0022-2275(20)33383-6 · DOI
  7. Bensinger, 2008, LXR signaling couples sterol metabolism to proliferation in the acquired immune response, Cell, 134, 97, 10.1016/j.cell.2008.04.052 · DOI · Paper page
  8. Birrell, 2008, Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth, Journal of Immunology, 181, 4265, 10.4049/jimmunol.181.6.4265 · DOI
  9. Boergesen, 2012, Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor alpha in mouse liver reveals extensive sharing of binding sites, Molecular and Cellular Biology, 32, 852, 10.1128/MCB.06175-11 · DOI
  10. Bonamassa, 2013, Atherosclerosis: Lessons from LXR and the intestine, Trends in Endocrinology and Metabolism, 24, 120, 10.1016/j.tem.2012.10.004 · DOI
  11. Bovenga, 2015, Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer, Cell Metabolism, 21, 517, 10.1016/j.cmet.2015.03.002 · DOI
  12. Bradley, 2007, Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE, The Journal of Clinical Investigation, 117, 2337, 10.1172/JCI31909 · DOI
  13. Brunham, 2006, Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels, Circulation Research, 99, 672, 10.1161/01.RES.0000244014.19589.8e · DOI · Paper page
  14. Casanova-Acebes, 2013, Rhythmic modulation of the hematopoietic niche through neutrophil clearance, Cell, 153, 1025, 10.1016/j.cell.2013.04.040 · DOI
  15. Chao, 2008, Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity, Journal of Medicinal Chemistry, 51, 5758, 10.1021/jm800612u · DOI
  16. Chen, 2007, Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice, Cell Metabolism, 5, 73, 10.1016/j.cmet.2006.11.012 · DOI
  17. Chen, 2012, Activation of liver X receptor induces macrophage interleukin-5 expression, The Journal of Biological Chemistry, 287, 43340, 10.1074/jbc.M112.403394 · DOI
  18. Courtaut, 2015, Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRbeta subcellular localization, Oncotarget, 6, 26651, 10.18632/oncotarget.5791 · DOI
  19. Crisafulli, 2010, Liver X receptor agonist treatment reduced splanchnic ischemia and reperfusion injury, Journal of Leukocyte Biology, 87, 309, 10.1189/jlb.0609438 · DOI
  20. Cui, 2011, Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation, The Journal of Clinical Investigation, 121, 658, 10.1172/JCI42974 · DOI
  21. Cui, 2012, Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice, Neuroscience, 210, 200, 10.1016/j.neuroscience.2012.02.047 · DOI
  22. Cyster, 2014, 25-Hydroxycholesterols in innate and adaptive immunity, Nature Reviews. Immunology, 14, 731, 10.1038/nri3755 · DOI · Paper page
  23. De Nardo, 2014, High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3, Nature Immunology, 15, 152, 10.1038/ni.2784 · DOI
  24. Derangere, 2014, Liver X receptor beta activation induces pyroptosis of human and murine colon cancer cells, Cell Death and Differentiation, 21, 1914, 10.1038/cdd.2014.117 · DOI
  25. DuSell, 2008, 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator, Molecular Endocrinology, 22, 65, 10.1210/me.2007-0383 · DOI
  26. Duval, 2006, Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine, Biochemical and Biophysical Research Communications, 340, 1259, 10.1016/j.bbrc.2005.12.137 · DOI
  27. Farnegardh, 2003, The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands, The Journal of Biological Chemistry, 278, 38821, 10.1074/jbc.M304842200 · DOI
  28. Feig, 2010, LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression, The Journal of Clinical Investigation, 120, 4415, 10.1172/JCI38911 · DOI
  29. Fessler, 2008, Liver X receptor: Crosstalk node for the signaling of lipid metabolism, carbohydrate metabolism, and innate immunity, Current Signal Transduction Therapy, 3, 75, 10.2174/157436208784223170 · DOI
  30. Fessler, 2016, The intracellular cholesterol landscape: Dynamic integrator of the immune response, Trends in Immunology, 37, 819, 10.1016/j.it.2016.09.001 · DOI
  31. Fessler, 2011, Intracellular lipid flux and membrane microdomains as organizing principles in inflammatory cell signaling, Journal of Immunology, 187, 1529, 10.4049/jimmunol.1100253 · DOI
  32. Fontaine, 2007, Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages, Circulation Research, 101, 40, 10.1161/CIRCRESAHA.106.135814 · DOI
  33. Fowler, 2003, Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production, The Journal of Investigative Dermatology, 120, 246, 10.1046/j.1523-1747.2003.12033.x · DOI
  34. Gadde, 2014, Development of therapeutic polymeric nanoparticles for the resolution of inflammation, Advanced Healthcare Materials, 3, 1448, 10.1002/adhm.201300688 · DOI
  35. Geyeregger, 2009, Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes, Journal of Leukocyte Biology, 86, 1039, 10.1189/jlb.1008663 · DOI
  36. Geyeregger, 2007, Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin, Blood, 109, 4288, 10.1182/blood-2006-08-043422 · DOI
  37. Ghisletti, 2009, Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways, Genes & Development, 23, 681, 10.1101/gad.1773109 · DOI
  38. Gold, 2014, 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling, Proceedings of the National Academy of Sciences of the United States of America, 111, 10666, 10.1073/pnas.1404271111 · DOI · Paper page
  39. Griffett, 2013, A liver-selective LXR inverse agonist that suppresses hepatic steatosis, ACS Chemical Biology, 8, 559, 10.1021/cb300541g · DOI
  40. Guillemot-Legris, 2016, Oxysterols in metabolic syndrome: From bystander molecules to bioactive lipids, Trends in Molecular Medicine, 22, 594, 10.1016/j.molmed.2016.05.006 · DOI
  41. He, 2014, Activation of liver-X-receptor alpha but not liver-X-receptor beta protects against myocardial ischemia/reperfusion injury, Circulation. Heart Failure, 7, 1032, 10.1161/CIRCHEARTFAILURE.114.001260 · DOI
  42. Heinz, 2010, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities, Molecular Cell, 38, 576, 10.1016/j.molcel.2010.05.004 · DOI · Paper page
  43. Hong, 2012, LXRalpha is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice, Journal of Lipid Research, 53, 1126, 10.1194/jlr.M022061 · DOI
  44. Hong, 2012, Coordinate regulation of neutrophil homeostasis by liver X receptors in mice, The Journal of Clinical Investigation, 122, 337, 10.1172/JCI58393 · DOI
  45. Hong, 2014, Liver X receptors in lipid metabolism: Opportunities for drug discovery, Nature Reviews. Drug Discovery, 13, 433, 10.1038/nrd4280 · DOI · Paper page
  46. Hu, 2010, Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration, Bioorganic & Medicinal Chemistry Letters, 20, 689, 10.1016/j.bmcl.2009.11.062 · DOI
  47. Hu, 2008, Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity, Bioorganic & Medicinal Chemistry Letters, 18, 54, 10.1016/j.bmcl.2007.11.013 · DOI
  48. Hu, 2009, Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta, Bioorganic & Medicinal Chemistry, 17, 3519, 10.1016/j.bmc.2009.04.012 · DOI
  49. Hu, 2010, Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist, Journal of Medicinal Chemistry, 53, 3296, 10.1021/jm100034x · DOI
  50. Hu, 2015, Sterol metabolism controls T(H)17 differentiation by generating endogenous RORgamma agonists, Nature Chemical Biology, 11, 141, 10.1038/nchembio.1714 · DOI
  51. Huang, 2015, Activation of LXR attenuates collagen-induced arthritis via suppressing BLyS production, Clinical Immunology, 161, 339, 10.1016/j.clim.2015.09.015 · DOI
  52. Huen, 2015, The role of systemic retinoids in the treatment of cutaneous T-cell lymphoma, Dermatologic Clinics, 33, 715, 10.1016/j.det.2015.05.007 · DOI · Paper page
  53. Ishibashi, 2013, Liver x receptor regulates arachidonic acid distribution and eicosanoid release in human macrophages: A key role for lysophosphatidylcholine acyltransferase 3, Arteriosclerosis, Thrombosis, and Vascular Biology, 33, 1171, 10.1161/ATVBAHA.112.300812 · DOI
  54. Ishikawa, 2013, LXRbeta/estrogen receptor-alpha signaling in lipid rafts preserves endothelial integrity, The Journal of Clinical Investigation, 123, 3488, 10.1172/JCI66533 · DOI
  55. Jakobsson, 2012, Liver X receptor biology and pharmacology: New pathways, challenges and opportunities, Trends in Pharmacological Sciences, 33, 394, 10.1016/j.tips.2012.03.013 · DOI · Paper page
  56. Jakobsson, 2014, The oxysterol receptor LXRbeta protects against DSS- and TNBS-induced colitis in mice, Mucosal Immunology, 7, 1416, 10.1038/mi.2014.31 · DOI
  57. Jakobsson, 2009, GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus, Molecular Cell, 34, 510, 10.1016/j.molcel.2009.05.006 · DOI
  58. Joseph, 2004, LXR-dependent gene expression is important for macrophage survival and the innate immune response, Cell, 119, 299, 10.1016/j.cell.2004.09.032 · DOI
  59. Joseph, 2002, Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proceedings of the National Academy of Sciences of the United States of America, 99, 7604, 10.1073/pnas.112059299 · DOI
  60. Kaneko, 2003, Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist, The Journal of Biological Chemistry, 278, 36091, 10.1074/jbc.M304153200 · DOI
  61. Kappus, 2014, Activation of liver X receptor decreases atherosclerosis in Ldlr(−)/(−) mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells, Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 279, 10.1161/ATVBAHA.113.302781 · DOI
  62. Katz, 2009, Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants, Journal of Clinical Pharmacology, 49, 643, 10.1177/0091270009335768 · DOI
  63. Kick, 2016, Discovery of highly potent liver X receptor beta agonists, ACS Medicinal Chemistry Letters, 7, 1207, 10.1021/acsmedchemlett.6b00234 · DOI
  64. Kim, 2015, Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor, The Journal of Clinical Investigation, 125, 183, 10.1172/JCI73615 · DOI
  65. Kirchgessner, 2015, Pharmacological characterization of a novel liver X receptor agonist with partial LXRalpha activity and a favorable window in nonhuman primates, The Journal of Pharmacology and Experimental Therapeutics, 352, 305, 10.1124/jpet.114.219923 · DOI
  66. Kirchgessner, 2016, Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils, Cell Metabolism, 24, 223, 10.1016/j.cmet.2016.07.016 · DOI · Paper page
  67. Kiss, 2011, Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRalpha, The American Journal of Pathology, 179, 92, 10.1016/j.ajpath.2011.03.019 · DOI
  68. Komati, 2017, Ligands of therapeutic utility for the liver X receptors, Molecules, 22, 10.3390/molecules22010088 · DOI
  69. Korach-Andre, 2015, Liver X receptors as regulators of metabolism, Biomolecular Concepts, 6, 177, 10.1515/bmc-2015-0007 · DOI
  70. Lalloyer, 2009, Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver, Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 1488, 10.1161/ATVBAHA.109.189506 · DOI
  71. Lappano, 2011, The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes, PLoS One, 6, 10.1371/journal.pone.0016631 · DOI
  72. Levin, 2005, Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists, Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 135, 10.1161/01.ATV.0000150044.84012.68 · DOI
  73. Li, 2013, NCoR repression of LXRs restricts macrophage biosynthesis of insulin-sensitizing omega 3 fatty acids, Cell, 155, 200, 10.1016/j.cell.2013.08.054 · DOI
  74. Lim, 2015, Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate, Bioconjugate Chemistry, 26, 2216, 10.1021/acs.bioconjchem.5b00203 · DOI
  75. Lin, 2016, The emerging roles of liver X receptors and their ligands in cancer, Expert Opinion on Therapeutic Targets, 20, 61, 10.1517/14728222.2015.1081169 · DOI
  76. Lo Sasso, 2010, Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis, Cell Metabolism, 12, 187, 10.1016/j.cmet.2010.07.002 · DOI
  77. Ma, 2017, Liver X receptors and their agonists: Targeting for cholesterol homeostasis and cardiovascular diseases, Current Issues in Molecular Biology, 22, 41, 10.21775/cimb.022.041 · DOI · Paper page
  78. Ma, 2008, 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway, American Journal of Physiology. Endocrinology and Metabolism, 295, E1369, 10.1152/ajpendo.90555.2008 · DOI
  79. Morales, 2008, Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke, Circulation, 118, 1450, 10.1161/CIRCULATIONAHA.108.782300 · DOI
  80. Mutemberezi, 2016, Oxysterols: From cholesterol metabolites to key mediators, Progress in Lipid Research, 64, 152, 10.1016/j.plipres.2016.09.002 · DOI
  81. Naik, 2006, Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo, Circulation, 113, 90, 10.1161/CIRCULATIONAHA.105.560177 · DOI
  82. Park, 2010, Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice, Rheumatology (Oxford), 49, 882, 10.1093/rheumatology/keq007 · DOI
  83. Patel, 2017, Separating the anti-inflammatory and diabetogenic effects of glucocorticoids through LXRbeta antagonism, Endocrinology, 158, 1034, 10.1210/en.2017-00094 · DOI
  84. Patel, 2011, LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice, The Journal of Clinical Investigation, 121, 431, 10.1172/JCI41681 · DOI
  85. Paterniti, 2017, Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson's disease, PLoS One, 12, 10.1371/journal.pone.0174470 · DOI
  86. Paterniti, 2010, Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma, Journal of Neurochemistry, 112, 611, 10.1111/j.1471-4159.2009.06471.x · DOI
  87. Peet, 1998, The LXRs: A new class of oxysterol receptors, Current Opinion in Genetics & Development, 8, 571, 10.1016/S0959-437X(98)80013-0 · DOI
  88. Pehkonen, 2012, Genome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages, BMC Genomics, 13, 50, 10.1186/1471-2164-13-50 · DOI
  89. Peng, 2008, Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice, The Journal of Pharmacology and Experimental Therapeutics, 327, 332, 10.1124/jpet.108.142687 · DOI
  90. Peng, 2011, A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(−/−) mice, British Journal of Pharmacology, 162, 1792, 10.1111/j.1476-5381.2011.01202.x · DOI · Paper page
  91. Pfeifer, 2011, Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol, Current Pharmaceutical Biotechnology, 12, 285, 10.2174/138920111794295774 · DOI
  92. Pourcet, 2011, LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8, Circulation Research, 109, 492, 10.1161/CIRCRESAHA.111.241810 · DOI · Paper page
  93. Quinet, 2009, LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse, Journal of Lipid Research, 50, 2358, 10.1194/jlr.M900037-JLR200 · DOI
  94. Raccosta, 2013, The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils, The Journal of Experimental Medicine, 210, 1711, 10.1084/jem.20130440 · DOI
  95. Ramezani, 2015, Stimulation of liver X receptor has potent anti-HIV effects in a humanized mouse model of HIV infection, The Journal of Pharmacology and Experimental Therapeutics, 354, 376, 10.1124/jpet.115.224485 · DOI
  96. Repa, 2000, Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta, Genes & Development, 14, 2819, 10.1101/gad.844900 · DOI
  97. Rong, 2013, LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition, Cell Metabolism, 18, 685, 10.1016/j.cmet.2013.10.002 · DOI
  98. Shi, 2016, The effect of a liver-X-receptor ligand on bleomycin induced pulmonary fibrosis in mice, International Immunopharmacology, 41, 116, 10.1016/j.intimp.2016.10.016 · DOI
  99. Shi, 2014, A liver-X-receptor ligand, T0901317, attenuates IgE production and airway remodeling in chronic asthma model of mice, PLoS One, 9
  100. Sironi, 2008, Treatment with LXR agonists after focal cerebral ischemia prevents brain damage, FEBS Letters, 582, 3396, 10.1016/j.febslet.2008.08.035 · DOI
  101. Smet, 2016, Cholesterol-sensing liver X receptors stimulate Th2-driven allergic eosinophilic asthma in mice, Immunity, Inflammation and Disease, 4, 350, 10.1002/iid3.118 · DOI
  102. Smoak, 2008, Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense, Journal of Immunology, 180, 3305, 10.4049/jimmunol.180.5.3305 · DOI
  103. Soroosh, 2014, Oxysterols are agonist ligands of RORgammat and drive Th17 cell differentiation, Proceedings of the National Academy of Sciences of the United States of America, 111, 12163, 10.1073/pnas.1322807111 · DOI
  104. Spann, 2012, Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses, Cell, 151, 138, 10.1016/j.cell.2012.06.054 · DOI
  105. Steffensen, 2013, Targeting liver X receptors in inflammation, Expert Opinion on Therapeutic Targets, 17, 977, 10.1517/14728222.2013.806490 · DOI
  106. Swahn, 2009, Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides, Bioorganic & Medicinal Chemistry Letters, 19, 2009, 10.1016/j.bmcl.2009.02.039 · DOI
  107. Tachibana, 2012, Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy, Journal of the American Society of Nephrology, 23, 1835, 10.1681/ASN.2012010022 · DOI
  108. Tangirala, 2002, Identification of macrophage liver X receptors as inhibitors of atherosclerosis, Proceedings of the National Academy of Sciences of the United States of America, 99, 11896, 10.1073/pnas.182199799 · DOI
  109. Temel, 2010, A new framework for reverse cholesterol transport: Non-biliary contributions to reverse cholesterol transport, World Journal of Gastroenterology, 16, 5946
  110. Temel, 2015, A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion, Trends in Pharmacological Sciences, 36, 440, 10.1016/j.tips.2015.04.002 · DOI
  111. Temel, 2010, Biliary sterol secretion is not required for macrophage reverse cholesterol transport, Cell Metabolism, 12, 96, 10.1016/j.cmet.2010.05.011 · DOI
  112. Torocsik, 2010, Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli, Journal of Immunology, 184, 5456, 10.4049/jimmunol.0902399 · DOI
  113. van der Veen, 2009, Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol, The Journal of Biological Chemistry, 284, 19211, 10.1074/jbc.M109.014860 · DOI
  114. Venteclef, 2010, GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response, Genes & Development, 24, 381, 10.1101/gad.545110 · DOI · Paper page
  115. Villablanca, 2010, Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses, Nature Medicine, 16, 98, 10.1038/nm.2074 · DOI
  116. Vizuete, 2017, Perspectives on nonalcoholic fatty liver disease: An overview of present and future therapies, Journal of Clinical and Translational Hepatology, 5, 67, 10.14218/JCTH.2016.00061 · DOI
  117. Walcher, 2006, LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes, Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1022, 10.1161/01.ATV.0000210278.67076.8f · DOI
  118. Walcher, 2010, LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration, Basic Research in Cardiology, 105, 487, 10.1007/s00395-010-0092-5 · DOI
  119. Wang, 2008, Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha, The Journal of Biological Chemistry, 283, 26332, 10.1074/jbc.M804808200 · DOI
  120. Wu, 2016, Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage, Journal of Neuroinflammation, 13, 62, 10.1186/s12974-016-0524-8 · DOI
  121. Yang, 2014, Activation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis, Investigative Ophthalmology & Visual Science, 55, 2795, 10.1167/iovs.13-13323 · DOI
  122. Yasuda, 2010, Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo, Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 781, 10.1161/ATVBAHA.109.195693 · DOI
  123. Yu, 2016, Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases, The FASEB Journal, 30, 2570, 10.1096/fj.201600244R · DOI
  124. Zelcer, 2006, Liver X receptors as integrators of metabolic and inflammatory signaling, The Journal of Clinical Investigation, 116, 607, 10.1172/JCI27883 · DOI · Paper page
  125. Zhang, 2012, Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice, The Journal of Clinical Investigation, 122, 1688, 10.1172/JCI59817 · DOI
  126. Zhang, 2015, Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis, Advanced Healthcare Materials, 4, 228, 10.1002/adhm.201400337 · DOI
  127. Zhang, 2015, Cholesterol metabolism and homeostasis in the brain, Protein & Cell, 6, 254, 10.1007/s13238-014-0131-3 · DOI · Paper page
  128. Zheng, 2016, Discovery of a novel, orally efficacious liver X receptor (LXR) beta agonist, Journal of Medicinal Chemistry, 59, 3264, 10.1021/acs.jmedchem.5b02029 · DOI

Cited by

Sorted by citations

Metadata

Authors
Fessler, M. B.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2018-01
Volume
181
Pages
1-12
ISSN
0163-7258
DOI
10.1016/j.pharmthera.2017.07.010
PMC
PMC5743771
Cited by
173
References
9
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
National Institute of Environmental Health Sciences (Z01 ES102005)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review